U.S. Markets open in 3 hrs 29 mins

Is Adaptimmune Therapeutics plc (ADAP) Undervalued?

Wade Goff

Adaptimmune Therapeutics plc (NASDAQ:ADAP), a biotechnology company based in United Kingdom, received a lot of attention from a substantial price increase on the NasdaqGS in the over the last few months. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Let’s take a look at ADAP’s outlook and value based on the most recent financial data to see if the opportunity still exists. View our latest analysis for Adaptimmune Therapeutics

Is ADAP still cheap?

According to my relative valuation model, ADAP seems to be currently fairly priced. I’ve used the price-to-book ratio in this instance because there’s not enough visibility to forecast its cash flows, and its earnings doesn’t seem to reflect its true value. The stock’s ratio of 3.1x is currently trading slightly below its industry peers’ ratio of 4.4x, which means if you buy ADAP today, you’d be paying a relatively fair price for it. And if you believe ADAP should be trading in this range, then there isn’t much room for the share price grow beyond what it’s currently trading. So, is there another chance to buy low in the future? Given that ADAP’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility.

Can we expect growth from ADAP?

NasdaqGS:ADAP Future Profit Nov 3rd 17

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. However, with an extremely negative double-digit change in profit expected over the next couple of years, near-term growth is certainly not a driver of a buy decision. It seems like high uncertainty is on the cards for ADAP, at least in the near future.

What this means for you:

Are you a shareholder? ADAP seems fairly priced right now, but given the uncertainty from negative returns in the future, this could be the right time to reduce the risk in your portfolio. Is your current exposure to the stock beneficial for your total portfolio? And is the opportunity cost of holding a negative-outlook stock too high? Before you make a decision on ADAP, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping an eye on ADAP for a while, now may not be the most advantageous time to buy, given it is trading around its fair value. The price seems to be trading at fair value, which means there’s less benefit from mispricing. Furthermore, the negative growth outlook increases the risk of holding the stock. However, there are also other important factors we haven’t considered today, which can help gel your views on ADAP should the price fluctuate below its true value.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Adaptimmune Therapeutics. You can find everything you need to know about ADAP in the latest infographic research report. If you are no longer interested in Adaptimmune Therapeutics, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.